SequelSEC

PULSE BIOSCIENCES, INC. PLSE

Surgical & Medical Instruments & Apparatus · CIK 0001625101 · Fiscal year ends 1231

Revenue
$350.00K
Fiscal year ended 2025-12-31
Operating income
-$76.94M
Fiscal year ended 2025-12-31
Free cash flow
-$54.44M
Fiscal year ended 2025-12-31

PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350.00K and net income of -$72.78M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from PULSE BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

PULSE BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$350.00K$0$0$700.00K$1.42M$0
Cost of revenue$539.00K$0$0$11.94M$1.97M$0
Gross profit-$189.00K$0Unavailable-$11.24M-$550.00K$0
Operating income-$76.94M-$56.26M-$43.57M-$58.06M-$63.01M-$49.96M
Net income-$72.78M-$53.58M-$42.21M-$58.50M-$63.66M-$49.85M
Research & development$44.72M$32.34M$27.80M$20.84M$28.64M$26.44M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income$72.80M$53.60M-$42.21M-$58.50M-$63.66M-$49.85M
Income tax expense$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$32.03M$23.92MUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$23.92M$15.78M$13.96M$19.07M$16.26M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PULSE BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$80.74M$118.04M$44.36M$61.14M$44.36M$12.46M
Total assets$94.54M$132.46M$59.15M$77.88M$59.15M$41.29M
Current assets$83.42M$119.45M$45.33M$62.15M$45.33M$22.34M
Total liabilities$13.88M$17.60M$14.79M$80.12M$14.79M$18.40M
Current liabilities$7.92M$10.06M$6.71M$5.98M$6.71M$7.58M
Total equity incl. NCI$80.66M$114.86M$44.36M-$2.25M$44.36M$22.89M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$136.00K$0Unavailable$0$5.82MUnavailable
Accounts receivable$274.00K$0Unavailable$0$61.00KUnavailable
Goodwill$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.78M$1.67M$1.84M$1.57M$1.84M$1.72M

Cash flow

PULSE BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$54.12M-$36.34M-$33.04M-$47.01M-$54.10M-$35.36M
Capital expenditures$315.00K$125.00K$121.00K$401.00K$437.00K$441.00K
Investing cash flow-$335.00K-$125.00K-$121.00K-$401.00K$7.56M$10.04M
Financing cash flow$17.15M$110.14M$16.39M$79.94M$62.68M$30.88M
Net change in cash-$37.30M$73.67M-$16.77M$32.52M$16.15M$5.56M
Stock-based compensation$21.46M$13.59M$7.18M$5.19M$14.60M$10.08M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PULSE BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$54.44M-$36.47M-$33.16M-$47.41M-$54.53M-$35.81M
Gross margin-54.0%UnavailableUnavailable-1606.3%-38.8%Unavailable
Operating margin-21982.6%UnavailableUnavailable-8293.9%-4443.9%Unavailable
FCF margin-15553.4%UnavailableUnavailable-6773.4%-3845.8%Unavailable
SBC / revenue6130.6%UnavailableUnavailable741.6%1029.7%Unavailable
Current ratio10.53x11.88x6.76x10.39x6.76x2.95x
Revenue YoY growthUnavailableUnavailable-100.0%-50.6%UnavailableUnavailable
Net margin-20794.6%UnavailableUnavailable-8357.9%-4489.4%Unavailable
R&D / revenue12777.4%UnavailableUnavailable2977.0%2019.7%Unavailable
CapEx / revenue90.0%UnavailableUnavailable57.3%30.8%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate0.0%0.0%UnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLSE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.